Journal
CNS SPECTRUMS
Volume 19, Issue 6, Pages 535-546Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852914000406
Keywords
anxious depression; assessment; depression
Categories
Funding
- Bristol- Myers Squibb, Co.
- Cerecor, Inc.
- Janssen Pharmaceutica
- Naurex, Inc.
- Pamlab, Inc.
- Ridge Diagnostics
- Shire Pic
- Takada Pharmaceuticals
- Novartis Pharmaceuticals
- Otsuka America
- Abbott Laboratories, Alkermes, Inc.
- American Cyanamid
- Aspect Medical Systems
- AstraZeneca
- BioResearch
- BrainCells Inc.
- Bristol- Myers Squibb
- CeNeRx BioPharma
- Cephalon
- Clintara, LLC
- Covance
- Covidien
- Eli Lilly and Company
- EnVivo Pharmaceuticals, Inc.
- Euthymics Bioscience, Inc.
- Forest Pharmaceuticals, Inc.
- Ganeden Biotech, Inc
- GlaxoSmithKline
- Harvard Clinical Research Institute
- Hoffman-LaRoche
- Icon Clinical Research
- i3 Innovus/Ingenix
- Janssen RD, LLC
- Jed Foundation
- Johnson & Johnson Pharmaceutical Research Development
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- MedAvante
- National Alliance for Research on Schizophrenia & Depression (NARSAD)
- National Institute of Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- Neuralstem, Inc.
- Novartis AG
- Organon Pharmaceuticals
- PamLab, LLC
- Pfizer Inc.
- Pharmacia-Upjohn, Pharmaceutical Research Associates, Inc.
- Pharmavite(R) LLC
- PharmoRx Therapeutics
- Photothera
- Roche Pharmaceuticals
- RCT Logic, Inc.
- Clinical Trials Solutions, LLC
- Sanofi-Aventis US LLC
- Shire
- Solvay Pharmaceuticals, Inc., Synthelabo
- Wyeth-Ayerst Laboratories
Ask authors/readers for more resources
Current measures for major depressive disorder focus primarily on the assessment of depressive symptoms, while often omitting other common features. However, the presence of comorbid features in the anxiety spectrum influences outcome and may effect treatment. More comprehensive measures of depression are needed that include the assessment of symptoms in the anxiety-depression spectrum. This study examines the reliability and validity of the Symptoms of Depression Questionnaire (SDQ), which assesses irritability, anger attacks, and anxiety symptoms together with the commonly considered symptoms of depression. Analysis of the factor structure of the SDQ identified 5 subscales, including one in the anxiety-depression spectrum, with adequate internal consistency and concurrent validity. The SDQ may be a valuable new tool to better characterize depression and identify and administer more targeted interventions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available